No photo of Nisha Anjali Mohindra

View Scopus Profile

Nisha Anjali Mohindra

  • 447 Citations
20082022
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Training Experience

2012Residency, Northwestern University, Feinberg School of Medicine
2015Fellowship, Northwestern University, Feinberg School of Medicine

Education/Academic qualification

MD, University of Texas - Southwestern

… → 2009

Fingerprint Dive into the research topics where Nisha Anjali Mohindra is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Tumor Burden Medicine & Life Sciences
Small Cell Lung Carcinoma Medicine & Life Sciences
Biomarkers Medicine & Life Sciences
Patient Selection Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2013 2022

Prot #D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II Lymph-node Negative

Mohindra, N. A.

AstraZeneca Pharmaceuticals LP

12/20/19 → 12/20/22

Project: Research project

54679793: Using the Novel 4R Patient Care Sequences to Improve the Duration and Outcomes of NSCLC Patients Receiving Targeted Treatment

Mohindra, N. A.

Pfizer Inc.

12/16/19 → 12/31/21

Project: Research project

Prot #M14-239: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Mohindra, N. A.

AbbVie Inc.

12/4/19 → 12/4/20

Project: Research project

Prot #BO39633: An Open-Label, Multicenter Extension and Long-Term Observational Study In Patients Previously Enrolled in a Genentech- and/or F. Hoffman-La Roche Ltd-Sponsored Atezolizumab Study

Mohindra, N. A.

Syneos Health, Inc., Genentech, Inc. and Hoffmann-La Roche Inc.

8/30/18 → 8/30/21

Project: Research project

Development of OncoLink: A Web-Based irAE Monitoring Platform

Mohindra, N. A., Penedo, F. J., Sosman, J. A. & Yanez, B. R.

Melanoma Research Alliance Foundation, Bristol-Myers Squibb Company

7/1/18 → 6/30/20

Project: Research project

Research Output 2008 2019

A review of eligibility for patients with central nervous system (CNS) metastases from non-small cell lung cancer (NSCLC) in immunotherapy clinical trials

Shaikh, S. S., Kumthekar, P. U. & Mohindra, N. A., Aug 15 2019, In : Journal of Neuro-Oncology. 144, 1, p. 235-237 3 p.

Research output: Contribution to journal › Letter

Non-Small Cell Lung Carcinoma
Immunotherapy
Central Nervous System
Clinical Trials
Neoplasm Metastasis
7 Citations (Scopus)

Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti–PD-1/PD-L1 Therapy in Non–Small-Cell Lung Cancer

Chae, Y. K., Davis, A. A., Raparia, K., Agte, S., Pan, A., Mohindra, N. A., Villaflor, V. M. & Giles, F., Mar 1 2019, In : Clinical Lung Cancer. 20, 2, p. 88-96.e6

Research output: Contribution to journal › Article

Tumor Burden
Non-Small Cell Lung Carcinoma
DNA Repair
Ligands
Mutation

Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer

Chae, Y. K., Viveiros, P., Lopes, G., Sukhadia, B., Sheikh, M. M., Saravia, D., Florou, V., Sokol, E. S., Frampton, G. M., Chalmers, Z. R., Ali, S. M., Ross, J. S., Chang, S., Wang, S., Chiec, L., Rahbari, A., Mohindra, N., Villaflor, V., Shin, S. H., Oh, M. & 5 others, Anker, J., Park, L. C., Wang, V., Chuang, J. & Park, W., Oct 2019, In : Journal of Thoracic Oncology. 14, 10, p. 1807-1817 11 p.

Research output: Contribution to journal › Article

Frameshift Mutation
Lung Neoplasms
Tumor Burden
Atlases
Renal Cell Carcinoma
4 Citations (Scopus)

Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer

Chae, Y. K., Davis, A. A., Agte, S., Pan, A., Simon, N. I., Iams, W. T., Cruz, M. R., Tamragouri, K., Rhee, K., Mohindra, N. A., Villaflor, V. M., Park, W., Lopes, G. & Giles, F. J., Jun 1 2019, In : Oncologist. 24, 6, p. 820-828 9 p.

Research output: Contribution to journal › Article

Tumor Burden
Non-Small Cell Lung Carcinoma
DNA
Neoplasms
Programmed Cell Death 1 Receptor
21 Citations (Scopus)

Management of immunotherapy-related toxicities, version 1.2019

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., Ernstoff, M. S., Frigault, M., Hoffner, B., Hoimes, C. J., Lacouture, M., Locke, F., Lunning, M., Mohindra, N. A., Naidoo, J., Olszanski, A. J. & 11 others, Oluwole, O., Patel, S. P., Reddy, S., Ryder, M., Santomasso, B., Shofer, S., Sosman, J. A., Wahidi, M., Wang, Y., Johnson-Chilla, A. & Scavone, J. L., Mar 2019, In : JNCCN Journal of the National Comprehensive Cancer Network. 17, 3, p. 255-289 35 p.

Research output: Contribution to journal › Article

Open Access
Immunotherapy
Guidelines
Oncology Nursing
Patient Advocacy
Neoplasms